文献速递心力衰竭与心肌病

恩格列净在非糖尿病射血分数降低心衰患者中的随机试验

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
PubMed 文献 · J Am Coll Cardiol · 2020-11-13

本研究为双盲安慰剂对照试验,纳入84例非糖尿病HFrEF患者,随机接受恩格列净10mg每日或安慰剂治疗6个月。主要终点为心脏磁共振评估的左室舒张末期和收缩末期容积变化。结果显示恩格列净显著降低左室容积和質量、改善射血分数、峰值耗氧量、6分钟步行距离及生活质量。

要点

  • 恩格列净显著降低非糖尿病HFrEF患者左室舒张末期和收缩末期容积。
  • 恩格列净改善左室射血分数、峰值耗氧量、6分钟步行距离和生活质量。
  • 获益独立于血糖状态,支持SGLT2抑制剂用于非糖尿病HFrEF患者。

核心结论

  • 恩格列净可显著改善非糖尿病HFrEF患者的左室容积、质量、收缩功能、功能容量和生活质量。
  • 观察结果强烈支持SGLT2抑制剂用于HFrEF患者治疗不依赖其血糖状态。

研究设计与样本

  • 双盲、安慰剂对照试验,纳入非糖尿病HFrEF患者n=84,随机接受恩格列净10mg每日或安慰剂治疗6个月。
  • 主要终点为心脏磁共振评估的左室舒张末期和收缩末期容积变化。

主要发现

  • 左室舒张末期容积变化:恩格列净组-25.1 ± 26.0 ml vs 安慰剂组-1.5 ± 25.4 ml,p < 0.001。
  • 左室收缩末期容积变化:恩格列净组-26.6 ± 20.5 ml vs 安慰剂组-0.5 ± 21.9 ml,p < 0.001。
  • 左室质量变化:恩格列净组-17.8 ± 31.9 g vs 安慰剂组4.1 ± 13.4 g,p < 0.001。
  • 左室射血分数变化:恩格列净组6.0 ± 4.2 vs 安慰剂组-0.1 ± 3.9,p < 0.001。
  • 峰值耗氧量变化:恩格列净组1.1 ± 2.6 ml/min/kg vs 安慰剂组-0.5 ± 1.9 ml/min/kg,p = 0.017;6分钟步行距离变化:恩格列净组81 ± 64 m vs 安慰剂组-35 ± 68 m,p < 0.001;KCCQ-12评分变化:恩格列净组21 ± 18 vs 安慰剂组2 ± 15,p < 0.001。

临床怎么用

  • 对于非糖尿病HFrEF患者,可考虑使用恩格列净以改善左室重构、功能容量和生活质量。

局限性

  • 样本量较小(n=84),需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Large clinical trials established the benefits of sodium-glucose cotransporter 2 inhibitors in patients with diabetes and with heart failure with reduced ejection fraction (HFrEF). The early and significant improvement in clinical outcomes is likely explained by effects beyond a reduction in hyperglycemia. OBJECTIVES: The purpose of this study was to assess the effect of empagliflozin on left ventricular (LV) function and volumes, functional capacity, and quality of life (QoL) in nondiabetic HFrEF patients. METHODS: In this double-blind, placebo-controlled trial, nondiabetic HFrEF patients (n = 84) were randomized to empagliflozin 10 mg daily or placebo for 6 months. The primary endpoint was change in LV end-diastolic and -systolic volume assessed by cardiac magnetic resonance. Secondary endpoints included changes in LV mass, LV ejection fraction, peak oxygen consumption in the cardiopulmonary exercise test, 6-min walk test, and quality of life. RESULTS: Empagliflozin was associated with a significant reduction of LV end-diastolic volume (-25.1 ± 26.0 ml vs. -1.5 ± 25.4 ml for empagliflozin vs. placebo, respectively; p < 0.001) and LV end-systolic volume (-26.6 ± 20.5 ml vs. -0.5 ± 21.9 ml for empagliflozin vs. placebo; p < 0.001). Empagliflozin was associated with reductions in LV mass (-17.8 ± 31.9 g vs. 4.1 ± 13.4 g, for empagliflozin vs. placebo, respectively; p < 0.001) and LV sphericity, and improvements in LV ejection fraction (6.0 ± 4.2 vs. -0.1 ± 3.9; p < 0.001). Patients who received empagliflozin had significant improvements in peak O2 consumption (1.1 ± 2.6 ml/min/kg vs. -0.5 ± 1.9 ml/min/kg for empagliflozin vs. placebo, respectively; p = 0.017), oxygen uptake efficiency slope (111 ± 267 vs. -145 ± 318; p < 0.001), as well as in 6-min walk test (81 ± 64 m vs. -35 ± 68 m; p < 0.001) and quality of life (Kansas City Cardiomyopathy Questionnaire-12: 21 ± 18 vs. 2 ± 15; p < 0.001). CONCLUSIONS: Empagliflozin administration to nondiabetic HFrEF patients significantly improves LV volumes, LV mass, LV systolic function, functional capacity, and quality of life when compared with placebo. Our observations strongly support a role for sodium-glucose cotransporter 2 inhibitors in the treatment of HFrEF patients independently of their glycemic status. (Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? [ATRU-4] [EMPA-TROPISM]; NCT03485222).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, et al. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2020. PMID: 33197559. doi:10.1016/j.jacc.2020.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。